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Diabetic nephropathy (DN) is a well-known complication of dia-
betes and leading cause of chronic renal failure and end-stage
renal disease (ESRD). Currently, angiotensin converting enzyme
inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) are
the standard of care for this disease although trials targeting
the renin-angiotensin-aldosterone system demonstrate that they
delay the progression to ESRD to only a limited extent [∼18%
relative risk reduction (Brenner et al., 2001; Lewis et al., 2001)].
Furthermore, dual-targeting of this pathway appears less-than-
promising, if not deleterious, as evidenced by the failure of the
recent ALTITUDE trial with the direct renin inhibitor, aliskiren,
where in combination with losartan, therapy reduced albumin-
uria but failed to impact glomerular filtration rate (Parving et al.,
2012). Thus, limited efficacy coupled with our incomplete under-
standing of this multifaceted disease highlights the importance
of unraveling novel targets based on a greater understanding of
the pathogenesis of renal impairment in diabetes. We must look
beyond ACE-Is/ARBs and capitalize on blending new technolo-
gies, target-disease associations, physiology-based insight, and
our enhanced ability to mine vast quantities of literature and data
as a means to identify new targets and then deliver novel drug
candidates into the clinic.
Various signaling pathways encompassing inflammation,
fibrosis, and oxidative stress are implicated in the pathogenesis
of DN (Reidy et al., 2014) and perhaps the key to novel and
efficacious therapies lays within the identification of druggable
targets that encompass these diverse processes. Can a population
of inflammatory cells be targeted to slow disease progression?
Or, should we look more closely to podocyte-selective targets
central to the regulation of glomerular filtration? Alternatively,
do we set our sights within the complicated environment of the
renal microvasculature? While early DN may represent an overtly
angiogenic environment, advanced disease likely represents a con-
dition of capillary loss and excess anti-angiogenic activity (Advani
and Gilbert, 2012). If so, can we reasonably target the renal
microvasculature in amanner expected to yield benefit across var-
ious stages of DN or might this type of targeted therapy treat only
a smaller subset of the DN population?
In this Research Topic, contributing authors explored four
sub-areas within the realm of chronic kidney disease and DN
including capitalizing on the discovery of novel mineralocor-
ticoid receptors with potentially lesser risk for hyperkalemia
(Orena et al., 2013), the potential for modulation of a secreted
glycoprotein already recognized as a contributor to minimal
change disease and now also as a target in DN (Chugh et al.,
2014), use of an endogenous anti-fibrotic peptide in renal dis-
ease (Kanasaki et al., 2014), and basic science that investigated
the expression of mitogen-activated protein kinases (MAPKs) in
podocytes as potential new targets in DN (Badshah et al., 2014),
an interesting area that may offer another pathway and novel
players for targeted therapies in this disease.
Indeed, results reported in this Research Topic by Orena et al.
(2013), who investigated renal protection against aldosterone-
mediated renal disease, in uninephrectomzied rats on high salt,
demonstrate the anti-proteinuric and renal anti-fibrotic effect
of PF-03882845 with a reduced risk of hyperkalemia compared
to traditional mineralocorticoid (MR) antagonist. Should these
findings translate to a greater safety profile in humans, this ther-
apy might constitute a significant and beneficial add-on to the
current standard of care.
Chugh et al. (2014) describe, in detail, the discovery of
angiopoietin-like protein 4 (ANGPTL4), secreted by podocytes,
as a major player in human nephrotic syndrome and highlight
the strategy used to identify and then selectively investigate genes
and proteins that lay at the intersection of proteinuria, hyperlipi-
demia, and edema during disease progression. They suggest that
sialylation-based, and recombinant mutated ANGPTL4-based,
therapeutics could hold promise in the treatment of common
forms of proteinuric kidney disease including DN. Moreover, it
could be envisioned that others could capitalize on a strategy sim-
ilar to that employed by the authors to identify additional novel
genes and proteins that could be targeted for the treatment of
human DN.
Investigating endogenous molecules as potential means for
identification of novel therapeutics, Kanasaki et al. (2014) discuss
novel therapeutic possibilities for renal disease and detail work
surrounding N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), a
substrate for ACE and theoretical candidate for anti-fibrotic ther-
apeutics.
A large body of published data suggests that podocytes play
a major role in the development of proteinuria and kidney dis-
ease by their ability to regulate glomerular filtration. Additionally,
analysis using samples from both type I and II diabetic patients
indicated that podocyte number is highly correlated with protein-
uria and appears to be one of the best disease predictors (White
et al., 2002). However, themechanisms of podocyte injury leading
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to foot process effacement and proteinuria are unclear. In the cur-
rent research topic, Badshah et al. (2014) investigated the role of
atypical MAP kinase Erk5 in mediating TGFβ1-induced podocyte
damage. Indeed, the role of ERK5 in the proliferation, apopto-
sis, and motility of cultured human podocytes was explored using
BIX02188, a novel Mek5 inhibitor that was experimentally shown
to reduce TGFβ1-induced Erk5 phosphorylation. They confirmed
the presence of three splice variants of Erk5 in human podocytes
that were phosphorylated by Mek5 in a TGFβ1-dependent man-
ner. TGFβ1-induced the proliferation and apoptosis of podocytes
while decreasing motility. While proliferation was reduced by
inhibiting Erk5 phosphorylation with BIX02188, no changes in
apoptosis or motility were observed. Most importantly, inhibition
of Mek5 with BIX02188 and subsequent loss of Erk5 phosphory-
lation, reduced TGFβ1-induced alterations of cellular phenotype,
as determined by a reduction in the expression of P-cadherin and
increased α-SMA, in addition to a reversal of TGFβ1-indcued
loss of barrier function. These results describe for the first time
the expression of Erk5 in podocytes and identify it as a potential
target for the treatment of diabetic renal disease.
Taken together, the findings highlighted in this research topic
provide novel insight into new or pre-existing pathways impli-
cated in disease. As researchers continue to seek and investigate
mechanisms causal of disease, the importance of biomarkers
predictors of efficacy should be emphasized. Novel biomark-
ers tailored toward the targeted pathways (such as inflamma-
tion, fibrosis, and endothelial function) and linked to disease
are urgently needed to provide clear efficacy signals in phase II
clinical trials and minimize further failures in phase III.
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